NDA 206302, held by Abbvie. Nebivolol Hydrochloride; Valsartan.
As of Nov 13, 2026, NDA 206302 (Byvalson), held by Abbvie, was first approved by FDA on Jun 3, 2016, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 3, 2016 | Original applicationNew combination · Standard review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| ByvalsonEQ 5MG BASE;80MG · tablet;oral | Nebivolol Hydrochloride; Valsartan | DiscontinuedReference drug |
| Jun 16, 2023 | Supplement 1Labeling · Standard review | Approved | |
| Jun 3, 2016 | Original applicationNew combination · Standard review | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters